Kilitch Drugs (India) Ltd
NSE:KILITCH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
300.8
460.95
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KILITCH stock under the Base Case scenario is 286.7 INR. Compared to the current market price of 329 INR, Kilitch Drugs (India) Ltd is Overvalued by 13%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Kilitch Drugs (India) Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for KILITCH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Kilitch Drugs (India) Ltd
Balance Sheet Decomposition
Kilitch Drugs (India) Ltd
Current Assets | 1.5B |
Cash & Short-Term Investments | 691m |
Receivables | 632.2m |
Other Current Assets | 136.6m |
Non-Current Assets | 940.7m |
Long-Term Investments | 228.5m |
PP&E | 481.2m |
Intangibles | 198.2m |
Other Non-Current Assets | 32.8m |
Current Liabilities | 642.2m |
Accounts Payable | 255.9m |
Short-Term Debt | 316.5m |
Other Current Liabilities | 69.8m |
Non-Current Liabilities | -4.5m |
Other Non-Current Liabilities | -4.5m |
Earnings Waterfall
Kilitch Drugs (India) Ltd
Revenue
|
1.5B
INR
|
Cost of Revenue
|
-954.9m
INR
|
Gross Profit
|
557.8m
INR
|
Operating Expenses
|
-395.6m
INR
|
Operating Income
|
162.2m
INR
|
Other Expenses
|
-36.4m
INR
|
Net Income
|
125.8m
INR
|
Free Cash Flow Analysis
Kilitch Drugs (India) Ltd
INR | |
Free Cash Flow | INR |
KILITCH Profitability Score
Profitability Due Diligence
Kilitch Drugs (India) Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Kilitch Drugs (India) Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
KILITCH Solvency Score
Solvency Due Diligence
Kilitch Drugs (India) Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Kilitch Drugs (India) Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KILITCH Price Targets Summary
Kilitch Drugs (India) Ltd
According to Wall Street analysts, the average 1-year price target for KILITCH is 475.32 INR with a low forecast of 470.66 INR and a high forecast of 489.3 INR.
Dividends
Current shareholder yield for KILITCH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kilitch Drugs (India) Ltd. engages in the manufacture and sale of pharmaceuticals, medicinal chemical, and botanical products. The company is headquartered in Mumbai, Maharashtra. The company is primarily engaged in the development, manufacturing, and marketing of finished dosages. The Company’s products include parenteral solutions, effervescent, nutritional products, and medical device. Its products categories include urinary alkalizer, cephalosporins products, gastroenterology, non steroidal anti-inflammatory drugs (NSAIDs), anticonvulsant/antiepileptic, adrenergic agonist, neurotonic, muscle relaxant/stimulant, aminoglycosides, anti-infective, anti-inflammatory, anti-malarials, anti-hypertensive, anaesthetic, uterine stimulants. Its parenteral solutions include neurotonic, veterinary products, metered nasal drops, vaccines, oncology, and ophthalmic products. Its effervescent products include Roipar, Duregra, And Roivit. The firm offers nutritional products, such as Celtine. The firm also offers medical devices, such as C-Seal.
Contact
IPO
Employees
Officers
The intrinsic value of one KILITCH stock under the Base Case scenario is 286.7 INR.
Compared to the current market price of 329 INR, Kilitch Drugs (India) Ltd is Overvalued by 13%.